Pancreatic ductal adenocarcinoma is projected to become the second-leading cause of cancer death in the United States by 2030 ...
The investigational combination of bezuclastinib (CGT9486) and sunitinib (Sutent) yielded clinically meaningful benefits with favorable tolerability in patients with gastrointestinal stromal tumors ...
A gastroenterologist at the Mayo Clinic who treats patients with pancreatic cancer shares the warning signs he looks for in ...
Pancreatic cancer is one of the deadliest types of tumors. A team at the Technical University of Munich (TUM) reports that ...
The biotech reported positive trial data for a treatment targeting patients with gastrointestinal stromal tumors.
Discusses Positive Phase 3 PEAK Trial Results of Bezuclastinib in Gastrointestinal Stromal Tumors November 8:00 ...
Cogent Biosciences (NASDAQ: COGT) shares skyrocketed over 120% after the biotech company announced groundbreaking results ...
In the medical field, being fast, efficient, and correct can be the difference between life and death. This game-changing tool is helping cancer researchers and doctors save lives. Bioinformatics ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback